Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

761. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia (Abstract)

Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia Persistent neuroleptic-induced movement disorders limit effective pharmacological management of psychotic disorders. Although antipsychotic switching is a common strategy for managing extrapyramidal side effects (EPSs), there is insufficient empirical support to guide the clinician. We designed the present study to examine whether patients with preexisting EPS switched to quetiapine (...) would show greater reduction in EPS compared with control patients.Twenty-two patients with schizophrenia meeting clinical criteria for tardive dyskinesia or coexisting parkinsonism were randomized either to switch from their current antipsychotic to quetiapine (n = 13) or to remain on their current treatment (n = 9). A battery of standard clinical assessments for EPS along with electromechanical instrumental measures was administered before randomization and again 1 and 3 months

2008 EvidenceUpdates Controlled trial quality: uncertain

762. Brief cognitive behaviour therapy improved insight and reduced negative symptoms and readmissions in schizophrenia Full Text available with Trip Pro

Brief cognitive behaviour therapy improved insight and reduced negative symptoms and readmissions in schizophrenia Brief cognitive behaviour therapy improved insight and reduced negative symptoms and readmissions in schizophrenia | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Brief cognitive behaviour therapy improved insight and reduced negative symptoms and readmissions in schizophrenia Article Text Treatment Brief cognitive behaviour

2008 Evidence-Based Nursing

763. Higher risk of offspring schizophrenia following antenatal maternal exposure to severe adverse life events Full Text available with Trip Pro

Higher risk of offspring schizophrenia following antenatal maternal exposure to severe adverse life events Most societies believe that a mother's psychological state can influence her unborn baby. Severe adverse life events during pregnancy have been consistently associated with an elevated risk of low birth weight and prematurity. Such events during the first trimester have also been associated with risk of congenital malformations.To assess the effect in offspring of antenatal maternal (...) exposure to an objective measure of stress on risk of adverse neurodevelopment, specifically schizophrenia. We hypothesized that the strongest relationship would be to maternal exposures during the first trimester.Population-based study.Denmark.In a cohort of 1.38 million Danish births from 1973 to 1995, mothers were considered exposed if 1 (or more) of their close relatives died or was diagnosed with cancer, acute myocardial infarction, or stroke syndrome up to 6 months before conception or during

2008 EvidenceUpdates

764. Nurse-led cognitive behaviour therapy improved insight and reduced negative symptoms and readmissions in schizophrenia

Nurse-led cognitive behaviour therapy improved insight and reduced negative symptoms and readmissions in schizophrenia Nurse-led cognitive behaviour therapy improved insight and reduced negative symptoms and readmissions in schizophrenia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Nurse-led cognitive behaviour therapy improved insight and reduced negative symptoms and readmissions in schizophrenia Article Text Therapeutics Nurse-led

2008 Evidence-Based Medicine

765. Review: aripiprazole for schizophrenia—more high quality research required

Review: aripiprazole for schizophrenia—more high quality research required Review: aripiprazole for schizophrenia—more high quality research required | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: aripiprazole for schizophrenia—more high quality research required Article Text Therapeutics Review: aripiprazole for schizophrenia—more high quality research required Statistics from Altmetric.com Request Permissions If you

2008 Evidence-Based Mental Health

766. Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia

Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia Article Text Therapeutics Risperidone improves symptoms in people who

2008 Evidence-Based Mental Health

767. Atypical antipsychotics for people with both schizophrenia and depression. Full Text available with Trip Pro

Atypical antipsychotics for people with both schizophrenia and depression. Many people (up to 50%) with schizophrenia also have co-morbid depression. It has been suggested that new atypical antipsychotic drugs are beneficial for people with the two diagnoses.To assess the effects of atypical antipsychotic drugs on people who have a diagnosis of both schizophrenia and depression.We searched the Cochrane Schizophrenia's Group Register (to March 2006). We supplemented this by citation searching (...) and personal contact with authors and relevant pharmaceutical companies.We included randomised clinical trials of atypical antipsychotic drugs used specifically for the treatment of people with a diagnosis of both schizophrenia and depression.We extracted data independently. For homogenous dichotomous data we calculated random effects, relative risk (RR), 95% confidence intervals (CI) and, where appropriate, numbers needed to treat (NNT) on an intention-to-treat basis. For continuous data, we calculated

2008 Cochrane

768. Review: Adding Chinese herbal medicine to antipsychotics may improve some outcomes in schizophrenia, but more high quality trials are needed

Review: Adding Chinese herbal medicine to antipsychotics may improve some outcomes in schizophrenia, but more high quality trials are needed Review: Adding Chinese herbal medicine to antipsychotics may improve some outcomes in schizophrenia, but more high quality trials are needed | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Adding Chinese herbal medicine to antipsychotics may improve some outcomes in schizophrenia, but more

2008 Evidence-Based Mental Health

769. Cognitive remediation therapy produces moderate improvements in working memory in people with schizophrenia

Cognitive remediation therapy produces moderate improvements in working memory in people with schizophrenia Cognitive remediation therapy produces moderate improvements in working memory in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cognitive remediation therapy produces moderate improvements in working memory in people with schizophrenia Article Text Therapeutics Cognitive remediation therapy produces

2008 Evidence-Based Mental Health

770. Metformin and lifestyle changes reduce antipsychotic-related weight gain in adults with schizophrenia

Metformin and lifestyle changes reduce antipsychotic-related weight gain in adults with schizophrenia Metformin and lifestyle changes reduce antipsychotic-related weight gain in adults with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin and lifestyle changes reduce antipsychotic-related weight gain in adults with schizophrenia Article Text Therapeutics Metformin and lifestyle changes reduce antipsychotic-related

2008 Evidence-Based Mental Health

771. Review: Children and adolescents with schizophrenia spectrum disorders respond to antipsychotics, but are susceptible to adverse events

Review: Children and adolescents with schizophrenia spectrum disorders respond to antipsychotics, but are susceptible to adverse events Review: Children and adolescents with schizophrenia spectrum disorders respond to antipsychotics, but are susceptible to adverse events | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Children and adolescents with schizophrenia spectrum disorders respond to antipsychotics, but are susceptible

2008 Evidence-Based Mental Health

772. Schizophrenia associated with increased risk of colon cancer but reduced risk of respiratory cancer

Schizophrenia associated with increased risk of colon cancer but reduced risk of respiratory cancer Schizophrenia associated with increased risk of colon cancer but reduced risk of respiratory cancer | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Schizophrenia associated with increased risk of colon cancer but reduced risk of respiratory cancer Article Text Aetiology Schizophrenia associated with increased risk of colon cancer

2008 Evidence-Based Mental Health

773. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study Knapp M, Windmeijer F (...) -effectiveness of olanzapine compared with other available antipsychotic medications, for the treatment of schizophrenic patients, previously or currently treated with medications related to schizophrenia, in a real-world clinical setting. Interventions Olanzapine was compared with risperidone, quetiapine, amisulpride, clozapine, and oral and depot typical antipsychotics. Location/setting 10 European countries/secondary care. Methods Analytical approach: The evaluation was based on the first 12-months

2008 NHS Economic Evaluation Database.

774. A systematic review of the soteria paradigm for the treatment of people diagnosed with schizophrenia

A systematic review of the soteria paradigm for the treatment of people diagnosed with schizophrenia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

775. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia Full Text available with Trip Pro

Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia Kumra S, Oberstar J V, Sikich L, Findling R L, McClellan J M, Vinogradov S, Schulz S C CRD summary The authors concluded that antipsychotic medications significantly reduce (...) the symptoms of early-onset schizophrenia spectrum disorder in children and adolescents, but extrapyramidal symptoms, sedation, prolactin elevation and weight gain are common. Although these conclusions appear justified by the data presented, it is difficult to assess their reliability given the rather limited search and poor reporting of the review. Authors' objectives To evaluate the use of antipsychotics for children and adolescents with early-onset schizophrenia spectrum (EOSS) disorder. Searching

2008 DARE.

776. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor

Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

777. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

778. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study Full Text available with Trip Pro

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost (...) in comparison with other prescribed oral treatments for patients with schizophrenia and suffering from acute exacerbations. The authors concluded that paliperidone was more effective and less expensive than other commonly prescribed antipsychotic drugs from the perspective of the Greek National Health System. The study was well conducted and satisfactorily presented. The authors’ conclusions appear to be valid. Type of economic evaluation Cost-effectiveness analysis Study objective The objective

2008 NHS Economic Evaluation Database.

779. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the clinical and economic impact of the oral atypical antipsychotics, aripiprazole, olanzapine, paliperidone extended release, quetiapine, risperidone, and ziprasidone, for the treatment of schizophrenia. The authors concluded that paliperidone extended

2008 NHS Economic Evaluation Database.

780. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes (...) in patients with schizophrenia Colombo GL, Caruggi M, Di Matteo S, Rossi A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared the cost-effectiveness of aripiprazole versus olanzapine for the treatment of patients

2008 NHS Economic Evaluation Database.